Pfizer statement on PhRMA-EFPIA principles
for responsible clinical trial data sharing
FRIDAY, 26 JULY 2013
Pfizer
The Pharmaceutical Research and
Manufacturers of America (PhRMA) and the
European Federation of Pharmaceutical
Industries and Associations (EFPIA) have
published new commitments for responsible
data sharing practices by biopharmaceutical
companies. The new commitments are designed
to expand access to clinical trial data and
advance science. They propose ways of sharing
data that will protect patient privacy, respect
the regulatory process, and preserve incentives
to undertake novel medical research for the
benefit of patients. We believe the solutions
offered by PhRMA and EFPIA provide a
responsible alternative to other approaches
currently being discussed in Europe.
Pfizer has been an active partner and
supporter in the development of these industry
commitments, which we fully support and will
adhere to in our policies and practices. We
have been and continue to be aligned with the
actions outlined in the commitments as part of
our ongoing efforts to optimize the use of our
clinical data to further medical research and
improve the quality of health care. Many of
our practices already meet or exceed the
standards established by PhRMA and EFPIA.
Pfizer participates in numerous data sharing
initiatives, publishes all clinical trial results
within 18 months of study completion, and
provides existing clinical data in response to
legitimate requests from researchers and
regulators.
We also have been a leader in making results
available and accessible to clinical trial
participants and will continue to expand our
sharing of information in meaningful ways to
inform and empower patients.
We are currently reviewing our policies to
ensure they fully reflect the new
commitments. An update to our public
disclosure policy will be issued later this year.
We welcome this opportunity to reaffirm
Pfizer's dedication to ensuring that the data
collected in the trials we conduct are
appropriately used in the service of public
health.
About Pfizer Inc.
At Pfizer, we apply science and our global
resources to bring therapies to people that
extend and significantly improve their lives.
We strive to set the standard for quality, safety
and value in the discovery, development and
manufacture of health care products. Our
global portfolio includes medicines and
vaccines as well as many of the world's best-
known consumer health care products. Every
day, Pfizer colleagues work across developed
and emerging markets to advance wellness,
prevention, treatments and cures that
challenge the most feared diseases of our time.
Consistent with our responsibility as one of the
world's premier innovative biopharmaceutical
companies, we collaborate with health care
providers, governments and local communities
to support and expand access to reliable,
affordable health care around the world. For
more than 150 years, Pfizer has worked to
make a difference for all who rely on us.
for responsible clinical trial data sharing
FRIDAY, 26 JULY 2013
Pfizer
The Pharmaceutical Research and
Manufacturers of America (PhRMA) and the
European Federation of Pharmaceutical
Industries and Associations (EFPIA) have
published new commitments for responsible
data sharing practices by biopharmaceutical
companies. The new commitments are designed
to expand access to clinical trial data and
advance science. They propose ways of sharing
data that will protect patient privacy, respect
the regulatory process, and preserve incentives
to undertake novel medical research for the
benefit of patients. We believe the solutions
offered by PhRMA and EFPIA provide a
responsible alternative to other approaches
currently being discussed in Europe.
Pfizer has been an active partner and
supporter in the development of these industry
commitments, which we fully support and will
adhere to in our policies and practices. We
have been and continue to be aligned with the
actions outlined in the commitments as part of
our ongoing efforts to optimize the use of our
clinical data to further medical research and
improve the quality of health care. Many of
our practices already meet or exceed the
standards established by PhRMA and EFPIA.
Pfizer participates in numerous data sharing
initiatives, publishes all clinical trial results
within 18 months of study completion, and
provides existing clinical data in response to
legitimate requests from researchers and
regulators.
We also have been a leader in making results
available and accessible to clinical trial
participants and will continue to expand our
sharing of information in meaningful ways to
inform and empower patients.
We are currently reviewing our policies to
ensure they fully reflect the new
commitments. An update to our public
disclosure policy will be issued later this year.
We welcome this opportunity to reaffirm
Pfizer's dedication to ensuring that the data
collected in the trials we conduct are
appropriately used in the service of public
health.
About Pfizer Inc.
At Pfizer, we apply science and our global
resources to bring therapies to people that
extend and significantly improve their lives.
We strive to set the standard for quality, safety
and value in the discovery, development and
manufacture of health care products. Our
global portfolio includes medicines and
vaccines as well as many of the world's best-
known consumer health care products. Every
day, Pfizer colleagues work across developed
and emerging markets to advance wellness,
prevention, treatments and cures that
challenge the most feared diseases of our time.
Consistent with our responsibility as one of the
world's premier innovative biopharmaceutical
companies, we collaborate with health care
providers, governments and local communities
to support and expand access to reliable,
affordable health care around the world. For
more than 150 years, Pfizer has worked to
make a difference for all who rely on us.
Comments
Post a Comment